Luis Tercedor

Luis Tercedor

Auto-generated profile, based on publicly available information

Luis Tercedor

Instituto de Investigación Biosanitaria ibs.GRANADA and Virgen de las Nieves University Hospital, Cardiology Department, Granada, Spain (E.C.-B., F.J.B.-J., P.J.S.-M., M.M.-L., M.A.-L., R.M.-R., L.T.-S., J.J.-J.).

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
LGLeticia Goni
Leticia Goni
VOVíctor de la O
Víctor de la O
MBM Teresa Barrio-López
M Teresa Barrio-López
PRPablo Ramos
Pablo Ramos
LTLuis Tercedor
Luis Tercedor
MRMiguel Ruiz-Canela
Miguel Ruiz-Canela
Background: The Prevention With Mediterranean Diet (PREDIMED) trial supported the effectiveness of a nutritional intervention conducted by a dietitian to prevent cardiovascular disease. However, the effect of a remote intervention to follow the Mediterranean diet has been less explored. Objective: This study aims to assess the effectiveness of a remotely provided Mediterranean diet–based nutritional intervention in obtaining favorable dietary changes in the context of a secondary prevention trial of atrial fibrillation (AF). Methods: The PREvention of recurrent arrhythmias with Mediterranean diet (PREDIMAR) study is a 2-year multicenter, randomized, controlled, single-blinded trial to assess the effect of the Mediterranean diet enriched with extra virgin olive oil (EVOO) on the prevention of atrial tachyarrhythmia recurrence after catheter ablation. Participants in sinus rhythm after ablation were randomly assigned to an intervention group (Mediterranean diet enriched with EVOO) or a control group (usual clinical care). The remote nutritional intervention included phone contacts (1 per 3 months) and web-based interventions with provision of dietary recommendations, and participants had access to a web page, a mobile app, and printed resources. The information is divided into 6 areas: Recommended foods, Menus, News and Online resources, Practical tips, Mediterranean diet classroom, and Your personal experience. At baseline and at 1-year and 2-year follow-up, the 14-item Mediterranean Diet Adherence Screener (MEDAS) questionnaire and a semiquantitative food frequency questionnaire were collected by a dietitian by phone. Results: A total of 720 subjects were randomized (365 to the intervention group, 355 to the control group). Up to September 2020, 560 subjects completed the first year (560/574, retention rate 95.6%) and 304 completed the second year (304/322, retention rate 94.4%) of the intervention. After 24 months of follow-up, increased adherence to the Mediterranean diet was observed in both groups, but the improvement was significantly higher in the intervention group than in the control group (net between-group difference: 1.8 points in the MEDAS questionnaire (95% CI 1.4-2.2; P<.001). Compared with the control group, the Mediterranean diet intervention group showed a significant increase in the consumption of fruits (P<.001), olive oil (P<.001), whole grain cereals (P=.002), pulses (P<.001), nuts (P<.001), white fish (P<.001), fatty fish (P<.001), and white meat (P=.007), and a significant reduction in refined cereals (P<.001), red and processed meat (P<.001), and sweets (P<.001) at 2 years of intervention. In terms of nutrients, the intervention group significantly increased their intake of omega-3 (P<.001) and fiber (P<.001), and they decreased their intake of carbohydrates (P=.02) and saturated fatty acids (P<.001) compared with the control group. Conclusions: The remote nutritional intervention using a website and phone calls seems to be effective in increasing adherence to the Mediterranean diet pattern among AF patients treated with catheter ablation. Trial Registration: ClinicalTrials.gov NCT03053843; https://www.clinicaltrials.gov/ct2/show/NCT03053843

1 December 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
Eva Cabrera-BorregoEva Cabrera-Borrego
Eva Cabrera-Borrego
FBFrancisco José Bermúdez-Jiménez
Francisco José Bermúdez-Jiménez
AGAlessio Gasperetti
Alessio Gasperetti
HTHarikrishna Tandri
Harikrishna Tandri
PSPablo J. Sánchez-Millán
Pablo J. Sánchez-Millán
JJJuan Jiménez Jáimez
Juan Jiménez Jáimez
BACKGROUND: Among inherited cardiomyopathies involving the left ventricle, whether dilated or not, certain genotypes carry a well-established arrhythmic risk, notably manifested as sustained monomorphic ventricular tachycardia (SMVT). Nonetheless, the precise localization and electrophysiological profile of this substrate remain undisclosed across different genotypes. METHODS: Patients diagnosed with cardiomyopathy and left ventricle involvement due to high-risk genetic variants and SMVT treated by electrophysiological study were recruited from 18 European/US centers. Electrophysiological study, imaging, and outcomes data after ablation were assessed in relation to genotype. RESULTS: Seventy-one patients were included (49.6 Q1–Q3 [40–60] years, 76% men). They were divided into 4 groups according to the affected protein: desmosomal ( DSP , PKP2 , DSG2 , and DSC2 ), nuclear membrane ( LMNA and TMEM43 ), cytoskeleton ( FLNC and DES ), and sarcoplasmic reticulum ( PLN ). Desmosomal genes, TMEM43 , and PLN were associated with biventricular disease, while variants in LMNA and cytoskeleton genes had predominant left ventricle involvement ( P =0.001). The location of the clinical-SMVT substrate was significantly different based on genotype ( P =0.005). DSP and cytoskeleton genes presented SMVTs with right bundle branch block morphology, which origin was identified in the inferolateral segments of the left ventricle. The other desmosomal genes ( PKP2 and DSG2 ), along with TMEM43 , showed SMVTs with left bundle branch block morphology and predominantly right ventricular substrate. In contrast, LMNA substrate was mainly observed in the interventricular septum. During a median of 26 Q1–Q3 (10.6–65) months, 27% of patients experienced recurrences of clinical SMVT with differences between genotypes (log-rank 0.016). Nuclear membrane genes demonstrated the highest recurrence rate compared with desmosomal genes (hazard ratio, 4.56 [95% CI, 1.5–13.8]). CONCLUSIONS: The anatomic substrate of SMVTs shows a strong correlation with the underlying genotype, electrocardiographic morphology, and recurrence rate. Particularly, patients with nuclear membrane gene variants have a significantly higher recurrence rate compared with those with desmosomal gene variants.

27 June 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
PÁPablo Ávila
Pablo Ávila
ABAntonio Berruezo
Antonio Berruezo
JJJavier Jiménez-Candil
Javier Jiménez-Candil
LTLuis Tercedor
Luis Tercedor
DCDavid Calvo
David Calvo
ÁAÁngel Arenal
Ángel Arenal
Background and aims: Bayesian analyses can provide additional insights into the results of clinical trials, aiding in the decision-making process. We analysed the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia (SURVIVE-VT) trial using Bayesian survival models. Methods and results: The SURVIVE-VT trial randomized patients with ischaemic cardiomyopathy and monomorphic ventricular tachycardia (VT) to catheter ablation or antiarrhythmic drugs (AAD) as a first-line strategy. The primary outcome was a composite of cardiovascular death, appropriate implantable cardioverter–defibrillator shocks, unplanned heart failure hospitalizations, or severe treatment-related complications. We used informative, skeptical, and non-informative priors with different probabilities of large effects to compute the posterior distributions using Markov Chain Monte Carlo methods. We calculated the probabilities of hazard ratios (HR) being <1, <0.9, and 98% probability of reducing the primary outcome (HR < 1) and a >96% probability of achieving a reduction of >10% (HR < 0.9). The probability of a >25% (HR < 0.75) reduction of treatment-related complications was >90%. Catheter ablation had a high probability (>93%) of reducing incessant/slow undetected VT/electric storm, unplanned hospitalizations for ventricular arrhythmias, and overall cardiovascular admissions > 25%, with absolute differences of 15.2%, 21.2%, and 20.2%, respectively. Conclusion: In patients with ischaemic cardiomyopathy and VT, catheter ablation as a first-line therapy resulted in a high probability of reducing several clinical outcomes compared to AAD. Our study highlights the value of Bayesian analysis in clinical trials and its potential for guiding treatment decisions. Trial Registration: ClinicalTrials.gov identifier: NCT03734562

3 October 2021 in Journal of Arrhythmia
Verified
Journal Article
Open access
PDF file
PSPablo J. Sánchez‐Millán
Pablo J. Sánchez‐Millán
GBGuillermo Gutièrrez Ballesteros
Guillermo Gutièrrez Ballesteros
MMManuel Mokina-Lerma
Manuel Mokina-Lerma
RMRosa Macías‐Ruiz
Rosa Macías‐Ruiz
JJJuan Jiménez Jáimez
Juan Jiménez Jáimez
MÁMiguel Álvarez
Miguel Álvarez
Background: Catheter ablation of premature ventricular complexes from aortic sinus cusps (ASC‐PVC) is a complex procedure that conventionally requires coronary catheterization (CC) to localize coronary artery ostium (CAO). Little published information is available on the mapping and ablation with zero‐fluoroscopy (ZF) of ASC‐PVC. The aim of the study was to determine the efficacy and safety of ASC‐PVC ablation with a ZF approach guided by 3D intracardiac echocardiography integration in the electroanatomical mapping system (ICE 3D‐EAM).Methods: This observational study included one patient cohort treated conventionally and another treated with ICE 3D‐EAM‐guided ZF ablation. Clinical, efficacy, and safety outcomes were evaluated acutely and at 3 months follow‐up.Results: The study included 21 patients with ASC‐PVC: 10 in the ZF group (age 49 ± 16 years, 60% males) and 11 in the control group (age 47 ± 15 years, 27% males). Fluoroscopy was not required for any patient in the ZF group. Acute success was obtained in 80% of the ZF group vs 55% of the control group (P = .36). The recurrence rate was 30% in the ZF group vs 27% in the control group (P = 1). One nonsevere complication was observed in the ZF group (P = .48).Conclusions: ZF catheter ablation of ASC‐PVC guided by ICE 3D‐EAM is feasible, effective, and safe.

1 July 2020 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
LJLaura Jordán-Martínez
Laura Jordán-Martínez
RRRicardo Rivera-López
Ricardo Rivera-López
FBFrancisco José Bermúdez-Jiménez
Francisco José Bermúdez-Jiménez
JJJuan Jiménez Jáimez
Juan Jiménez Jáimez
JAJavier Alzueta
Javier Alzueta
LTLuis Tercedor
Luis Tercedor

1 November 2019 in Revista Espanola de Cardiologia
Verified
Journal Article
Closed access
FPFrancesca Perin
Francesca Perin
JTJuan Pablo Trujillo-Quintero
Juan Pablo Trujillo-Quintero
JJJuan Jiménez Jáimez
Juan Jiménez Jáimez
MRMaría del Mar Rodríguez-Vázquez del Rey
María del Mar Rodríguez-Vázquez del Rey
LMLorenzo Monserrat
Lorenzo Monserrat
LTLuis Tercedor
Luis Tercedor